Revival of nifedipine, a dihydropyridine-based calcium blocker

Medical Hypotheses

Volumn 68, Issue 3, 2007, Pages 565-567

  Yamagishi, S ^a   Nakamura, K ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LONG ACTING DRUG; NIFEDIPINE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RISK REDUCTION; STABLE ANGINA PECTORIS; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME;

ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MULTICENTER STUDIES AS TOPIC; NIFEDIPINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ANGINA;

EID: 33845922727     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.05.070     Document Type: Article

References (19)

1. Black H.R. The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure. Am J Hypertens 9 (2003) 4S-6S
2. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362 (2003) 1527-1535
4. Chapman N., and Neal B. Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes. Curr Hypertens Rep 3 (2001) 340-349
5. Nathan S., Pepine C.J., and Bakris G.L. Calcium antagonists. Effects on cardio-renal risk in hypertensive patients. Hypertension 46 (2005) 637-642
6. Kloke H.J., Branten A.J., Huysmans F.T., and Wetzels J.F. Antihypertensive treatment of patients with proteinuric renal disease: risks or benefits of calcium channel blockers?. Kidney Int 53 (1998) 1559-1573
7. Bakris G.L., Weir M.R., Secic M., Campbell B., and Weis-McNulty A. Different effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65 (2004) 1991-2002
8. Sisson S.D., Rastegar D., Rice T.N., Prokopowicz G., and Hughes M.T. Physician familiarity with diagnosis and management of hypertension according to JNC 7 guidelines. Clin Hypertens 8 (2006) 344-350
9. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: p. 1-290.
10. Poole-Wilson P.A., Lubsen J., Kirwan B.A., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
11. Moe G.W., Martin-Garcia J., Konig A., et al. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 287 (2004) H1813-H1820
12. Suematsu N., Tsutsui H., Wen J., et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107 (2003) 1418-1423
13. Yamagishi S., Inagaki Y., Abe R., et al. Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha. Drugs Exp Clin Res 29 (2003) 141-145
14. Yamagishi S., Inagaki Y., and Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 29 (2003) 147-152
15. Baba S. J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54 (2001) 191-201
16. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37 (1998) 586-600
17. Schmidt A.M., and Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2 (2000) 430-436
18. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
19. Yamagishi S., and Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 30 (2004) 169-175